{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:10:48Z","timestamp":1773807048173,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Aim: Among NF1-dependent tumors, the most common are optic pathway gliomas (OPGs). The objective of this study was the retrospective analysis of the course, indications for treatment, and effects of therapy for NF1-OPGs. Patients and Methods: We analyzed demographics, clinical and genetic data, imaging and ophthalmological parameters, their impact on therapeutic decisions, and the effectiveness of the therapy in 92 patients. Results: OPGs were unilateral in 55.4% of patients and bilateral in 44.6%. Post-contrast enhancement in MRI was observed in 67.4%. Oncological treatment was required in 16.3% of patients with median age 3.8 years. Factors significant in multivariate analysis contributing to the need of oncological treatment were: amblyopia and proptosis. Factors contributing to amblyopia were: strabismus, proptosis, co-occurrence of epilepsy, bilateral OPGs, and thickness of the optic nerve \u2265 8 mm. The first line of oncological treatment included vincristine + carboplatin or monotherapy with vinblastine. The use of subsequent lines of oncological treatment was necessary in 46.7% patients. Conclusions: The following conclusions, suggest modification of the approach in the management of patients with NF1-OPG, summarize the presented study: (1) perform the first MRI after the age of 1 year, (2) reduce the frequency of follow-up scans in the first year of observation in patients with isolated involvement of intraocular and\/or intraorbital segments of the optic nerve, (3) refrain from administering contrast during control MRI examinations of the orbits after OPG diagnosis; (4) in patients with co-occurring psychomotor delay or treated with antiepileptic drugs, do not make decisions about oncological therapy when visual acuity deterioration is observed, without progression in optical coherence tomography (OCT), visual evoked potentials (VEP), and MRI.<\/jats:p>","DOI":"10.3390\/cancers17091404","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:38:37Z","timestamp":1745390317000},"page":"1404","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors in Optic Pathway Gliomas in Neurofibromatosis Type 1: A Single Center Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2220-9863","authenticated-orcid":false,"given":"Agata","family":"Marja\u0144ska","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Jurasz University Hospital, 85-095 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagoda","family":"Styczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Jurasz University Hospital, 85-095 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Jatczak-Gaca","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Jurasz University Hospital, 85-095 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-6088","authenticated-orcid":false,"given":"Joanna","family":"Stachura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Collegium Medicum, Nicolaus Copernicus University Torun, Jurasz University Hospital, 85-095 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Marja\u0144ski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Clinical Oncology, Oncology Center, Bydgoszcz University of Science and Technology, 85-796 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3158-119X","authenticated-orcid":false,"given":"Jan","family":"Styczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Jurasz University Hospital, 85-095 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101818","DOI":"10.1016\/j.eclinm.2022.101818","article-title":"ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1","volume":"56","author":"Carton","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IJG.0b013e3182934978","article-title":"Anatomy of the visual pathways","volume":"22","year":"2013","journal-title":"J. Glaucoma"},{"key":"ref_3","unstructured":"(2025, February 25). The Visual Pathway of the Brain. Available online: https:\/\/www.brainkart.com\/article\/The-Visual-Pathway-of-the-Brain_19029\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cassina, M., Frizziero, L., Opocher, E., Parrozzani, R., Sorrentino, U., Viscardi, E., Miglionico, G., Midena, E., Clementi, M., and Trevisson, E. (2019). Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations. Cancers, 11.","DOI":"10.3390\/cancers11111790"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","article-title":"Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848","volume":"102","author":"Koczkowska","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00439-023-02555-z","article-title":"Analysis of 200 unrelated individuals with a constitutional NF1 deep intronic pathogenic variant reveals that variants flanking the alternatively spliced NF1 exon 31 [23a] cause a classical neurofibromatosis type 1 phenotype while altering predominantly NF1 isoform type II","volume":"142","author":"Koczkowska","year":"2023","journal-title":"Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/aje\/kwm203","article-title":"Allergic conditions and brain tumor risk","volume":"166","author":"Wigertz","year":"2007","journal-title":"Am. J. Epidemiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.1038\/s41467-021-27455-6","article-title":"Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia","volume":"12","author":"Chatterjee","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic Pathway Gliomas in Neurofibromatosis Type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J. Child Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/CMAR.S362678","article-title":"Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects","volume":"15","author":"Tang","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/1120672120906989","article-title":"Role of visual evoked potentials and optical coherence tomography in the screening for optic pathway gliomas in patients with neurofibromatosis type I","volume":"31","author":"Vagge","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.14791\/btrt.2022.0006","article-title":"Recent Update in Pharmacological Agents for Optic Pathway Glioma","volume":"10","author":"Park","year":"2022","journal-title":"Brain Tumor. Res. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","article-title":"Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas","volume":"86","author":"Packer","year":"1997","journal-title":"J. Neurosurg."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Dal Bello, S., Martinuzzi, D., Tereshko, Y., Veritti, D., Sarao, V., Gigli, G.L., Lanzetta, P., and Valente, M. (2023). The Present and Future of Optic Pathway Glioma Therapy. Cells, 12.","DOI":"10.3390\/cells12192380"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/WNO.0000000000000550","article-title":"Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision","volume":"37","author":"Fisher","year":"2017","journal-title":"J. Neuro-Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma","volume":"30","author":"Bouffet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rajagopal, R., Khan, M., Lethbridge, R., Lee, G., Lee, S., Dyke, J., Fabian, V., McGrath, A., Taylor, M., and Jacoby, P. (2023). Long-term outcomes of symptomatic optic pathway glioma: 32-year experience at a single Western Australian tertiary pediatric oncology center. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1157909"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Neurofibromatosis (1988). Conference statement. National Institutes of Health Consensus Development Conference. Arch. Neurol., 45, 575\u2013578.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jalz.2019.07.012","article-title":"Undetectable gadolinium brain retention in individuals with an age-dependent blood-brain barrier breakdown in the hippocampus and mild cognitive impairment","volume":"15","author":"Montagne","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging","volume":"275","author":"McDonald","year":"2015","journal-title":"Radiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1007\/s00247-018-4154-4","article-title":"Surveillance magnetic resonance imaging for isolated optic pathway gliomas: Is gadolinium necessary?","volume":"48","author":"Maloney","year":"2018","journal-title":"Pediatr. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00234-019-02198-w","article-title":"Diagnostic performance of an unenhanced MRI exam for tumor follow-up of the optic pathway gliomas in children","volume":"61","author":"Marsault","year":"2019","journal-title":"Neuroradiology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11060-021-03941-1","article-title":"Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma\u2013A retrospective Magnetic Resonance Imaging study","volume":"156","author":"Kilian","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00381-020-04706-3","article-title":"Visual function tests including the role of optical coherence tomography in neurofibromatosis 1","volume":"36","author":"Zur","year":"2020","journal-title":"Childs Nerv. Syst."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.3171\/FOC-07\/11\/E1","article-title":"Neuroophthalmological management of optic pathway gliomas","volume":"23","author":"Lee","year":"2007","journal-title":"Neurosurg. Focus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.4103\/IJO.IJO_2802_22","article-title":"Evaluation of ganglion cell complex and retinal nerve fiber layer thinning in epilepsy patients","volume":"71","author":"Duran","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1059-1311(03)00082-7","article-title":"The effect of antiepileptic drugs on visual performance","volume":"13","author":"Hilton","year":"2004","journal-title":"Seizure"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/epi4.13004","article-title":"The thickness of the retinal nerve fiber layer, macula, and ganglion cell-inner plexiform layer in people with drug-resistant epilepsy","volume":"9","author":"Chen","year":"2024","journal-title":"Epilepsia Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/1055-9965.EPI-15-0847","article-title":"Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study","volume":"25","author":"Amirian","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_31","first-page":"10","article-title":"Epidemiology of allergic diseases in Poland","volume":"1","author":"Raciborski","year":"2014","journal-title":"Pol. J. Allergol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: A canadian pediatric brain tumor consortium study","volume":"34","author":"Lasaletta","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e31337","DOI":"10.1002\/pbc.31337","article-title":"Optic pathway gliomas in children: Clinical characteristics, treatment, and outcome of 95 patients in a single center over a 31-year period. Can we avoid radiotherapy?","volume":"71","author":"Kebudi","year":"2024","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11060-017-2517-6","article-title":"Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1","volume":"134","author":"Trevisson","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jpeds.2015.07.001","article-title":"The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1","volume":"167","author":"Prada","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ajmg.a.20650","article-title":"Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1","volume":"127","author":"Blazo","year":"2004","journal-title":"Am. J. Med. Genet.-Part A"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/neuonc\/noaa153","article-title":"NF1 optic pathway glioma: Analyzing risk factors for visual outcome and indications to treat","volume":"23","author":"Azizi","year":"2021","journal-title":"Neuro. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/01.wnl.0000435745.95155.b8","article-title":"Functional outcome measures for NF1-associated optic pathway glioma clinical trials","volume":"81","author":"Fisher","year":"2013","journal-title":"Neurology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1404\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:19:54Z","timestamp":1760030394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091404"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091404","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}